Dr. Joseph Gabriele is a molecular pharmacologist and award-winning innovator specializing in signal transduction, transdermal delivery, and formulation chemistry. As Chief Scientific Officer at TruNorth Naturals, he brings decades of expertise in pharmaceutical sciences and natural product research to guide the company’s science-driven product development and R&D strategy.

Dr. Gabriele holds a B.Sc. from the University of Toronto, M.Sc. and Ph.D. degrees from McMaster University, and completed postdoctoral training at Queen’s University. He has lectured widely across North America and Europe and remains at the forefront of innovation in therapeutic delivery systems and molecular pharmacology.

As co-founder of Delivra Corp, Dr. Gabriele developed the delivra™ transdermal delivery platform—an advanced system capable of transporting small biologics and large peptides across the skin in a targeted and efficient manner. His work has earned numerous distinctions, including the CIHR Studentship Award, NSERC Canada Graduate Scholarship, Ontario Mental Health Foundation Postdoctoral Fellowship, the International Congress on Schizophrenia Research “New Investigator Award,” and the Hamilton Health Sciences “New Investigator Award.” In 2018, he was named Ernst & Young Entrepreneur of the Year in Health Care.

At TruNorth, Dr. Gabriele leads efforts to develop cutting-edge mushroom-based products with enhanced bioavailability and therapeutic potential. His team operates from a molecular biology and analytics lab in Prince Edward Island, in collaboration with the National Research Council of Canada and Agriculture Canada. His leadership is helping bridge traditional medicine with modern science to bring advanced, high-integrity natural health products to market.